Percutaneous technologies to correct TR : Myth or Reality? Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan

Similar documents
Concomitant Tricuspid Valve Repair :

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Percutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions

3D Echo for Evaluation of Tricuspid Regurgitation Jong-Min Song, MD, PhD

What are the indications for Tricuspid valve repair during LVAD Implant RANJIT JOHN, MD UNIVERSITY OF MINNESOTA

Surgical AF Ablation : Lesion Sets and Energy Sources. What are the data? Steven F Bolling, MD Cardiac Surgery University of Michigan

Next Generation Therapies: Aortic, Mitral and Beyond

Management of Tricuspid Regurgitation

Imaging to select patients for Transcatheter TV

Management of TR in Patients Undergoing Mitral Interventions

MITRAL VALVE PATHOLOGY WITH TRICUSPID REGURGITATION (AND PHT)

Overview of Surgical Approach to Mitral Valve Disease : Why Repair? Steven F. Bolling, MD Cardiac Surgery University of Michigan

Prognostic Impact of FMR

Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz

Atrioventricular valve repair: The limits of operability

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Edwards' solution for patients suffering from tricuspid valve disease

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

Clinical Outcome of Tricuspid Regurgitation. David Messika-Zeitoun

Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.

The Key Questions in Mitral Valve Interventions. Where Are We in 2018?

Primary Mitral Valve Disease: Natural History & Triggers for Intervention ACC Latin American Conference 2017

Objectives. Considerations in management of multivalvular disease. Case Discussions. A Systematic Approach to Multivalve Disease.

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE

Percutaneous mitral annuloplasty. Francesco Maisano MD, FESC San Raffaele Hospital Milano, Italy

The FORMA Early Feasibility Study: 30-Day Outcomes of Transcatheter Tricuspid Valve Therapy in Patients with Severe Secondary Tricuspid Regurgitation

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

The Tricuspid Valve: The Not So Forgotten Valve. Manuel J Antunes Cardiothoracic Surgery Coimbra, Portugal

Percutaneous mitral valve repair/replacement. Jan Van der Heyden MD, PhD St.Antonius Hospital Nieuwegein

Transcatheter Mitral Innovations, Part II. Michael Mack, M.D. Baylor Scott & White Health

Transcatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President

Understanding the guidelines for Interventions in MR. Ali AlMasood

Transcatheter Mitral Valve for fmr: The Era of Too Many Options

Ανεπάρκεια Τριγλώχινας Επιλογή Επεμβατικής Θεραπείας. Μ. Χρυσοχέρης Τμήμα Διαδερμικών Βαλβίδων ΔΘΚΑ ΥΓΕΙΑ

Moderate TR Should be Repaired at the Time of LVAD Con. James Kirklin MD

Which Type of Secondary Tricuspid Regurgitation Accompanying Mitral Valve Disease Should Be Surgically Treated?

What is Ebstein Anomaly?

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

Assessment of Tricuspid and Pulmonic Valve Disease: Importance of 3D

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

Which patient undergoing mitral valve surgery should also have the tricuspid repair?

NeoChord Mitral Valve Repair. Department of Cardiac, Thoracic and Vascular Sciences University of Padua, Italy

Tricuspid leaflet repair: innovative solutions

Surgery For Ebstein Anomaly

Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain

Trans-catheter TV repair Leaflet or Annuloplasty Techniques

Isolated tricuspid valve surgery: timing and indications

Prof. Patrizio LANCELLOTTI, MD, PhD Heart Valve Clinic, University of Liège, CHU Sart Tilman, Liège, BELGIUM

Tricuspid and Pulmonary Valve Disease

Valvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD

Current status: Percutaneous mitral valve therapy

JOINT MEETING 2 Tricuspid club Chairpersons: G. Athanassopoulos, A. Avgeropoulou, M. Khoury, G. Stavridis

Mitral Regurgitation

Percutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today?

Assessing the Impact on the Right Ventricle

Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical. The Houston Aortic Symposium February 23-25, 2017

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας

Imaging MV. Jeroen J. Bax Leiden University Medical Center The Netherlands Davos, feb 2015

Mitral valve treatment in advanced heart failure: Repair, Replacement, MitraClip. Nicola Buzzatti, MD San Raffaele Scientific Institute Milan, Italy

Chronic Primary Mitral Regurgitation

Mitral Valve Disease. James Hermiller, MD, FACC, FSCAI St Vincent Heart Center Indianapolis, IN

When Does 3D Echo Make A Difference?

Surgical Options to Prevent and Treat Tricuspid Valve Regurgitation in Heart Transplant Recipients

Repair or Replacement

Right Heart Failure in LVAD patients: Prevention and Management.

ΓΙΩΡΓΟΣ ΜΑΚΑΒΟΣ, MD, PhD ΚΑΡΔΙΟΛΟΓΟΣ, ΕΠΙΜΕΛΗΤΗΣ Β Γ ΠΑΝΕΠΙΣΤΗΜΙΑΚΗ ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Γ.Ν.Ν.Θ.Α. ΣΩΤΗΡΙΑ

Right Ventricular Failure: Prediction, Prevention and Treatment

Prof. JL Zamorano Hospital Universitario Ramón y Cajal

What is the Role of Surgical Repair in 2012

Deok Young Choi, Gil Hospital, Gachon University NEONATES WITH EBSTEIN S ANOMALY: PROBLEMS AND SOLUTION

Transcatheter Mitral and Tricuspid Therapies

Aortic Stenosis Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan

Index. B B-type natriuretic peptide (BNP), 76

Surgical Approach To Functional MR: One Size Does Not Fit All

I have financial relationships to disclose Honoraria from: Edwards

Percutaneous Repair for MR:

Really Less-Invasive Trans-apical Beating Heart Mitral Valve Repair: Which Patients?

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

Quality Outcomes Mitral Valve Repair

Emerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX

Mitral Repair/AF Ablation Sternotomy Approach

Επιδιόπθωζη μιηποειδικήρ ζςζκεςήρ ζε ππόπηωζη ή πήξη γλωσίνων. Βαζίλειορ Σασπεκίδηρ Επιμεληηήρ Β Καπδιολογίαρ Γ.Ν. Παπαγεωπγίος

Evaluation of the Right Ventricle in Candidates for Right Ventricular Assist Device Implantation.

Management of Difficult Aortic Root, Old and New solutions

Successful Percutaneous Closure of Mitral Bioprosthetic Paravalvular Leak Using Figulla ASD Occluder

Late Outcome of Tricuspid Annuloplasty Using a Flexible Band/Ring for Functional Tricuspid Regurgitation

Primary Mitral Regurgitation

DISCLOSURE. Mitral ViV: why? Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? UW Medicine NONE.

Transcatheter Mitral Valve Interventions: Clinical Indications. Didier TCHETCHE, MD. Clinique Pasteur, Toulouse, France.

Ioannis Alexanian, MD, PhD Department of Cardiology General Hospital of Chest Diseases Sotiria Athens

Tricuspid valve surgery in patients with a systemic right ventricle

What echo measurements are key prior to MitraClip?

Mitral Valve Disease, When to Intervene

Percutaneous Mitral Valve Repair

Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?

What Degree of MR Deserves Surgical or Transcatheter Intervention, and How Should It Be Assessed?

Update on Transcatheter Mitral Valve Repair and Replacment

Valvular Intervention

Transcription:

Percutaneous technologies to correct TR : Myth or Reality? Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan

Disclosures Ownership Interest: Millipede and Pipeline

TR is BAD Decreased CO Fatigue, decreased exercise tolerance Right-sided Heart Failure Ascites, edema, decreased appetite, fullness FTR - feel terrible Valve repair for functional tricuspid valve regurgitation: anatomical and surgical considerations Rogers JH, Bolling SF Semin Thorac Cardiovasc Surg. 2010 ;22(1):84-9

FTR increases Mortality Severe and MODERATE TR increase mortality independent of PASP, LVEF, IVC size, RV size/ function, 5223 pts Nath. JACC 2004;43:405.

Severe and MODERATE TR decreases survival Having TR is BAD! Topilsky. JACC 2014.

TR after MitraClip for FMR TR Severity Death/Rehosp Ohno et al. EHJ 2014;15:1246. More TR at baseline - worse outcome Moderate or Severe TR is BAD even percutaneously!

FTR : Reality Mod /severe TR - BAD

Pathophysiology of Functional / Secondary TR What size? NORMAL TRICUSPID ANNULAR DIMENSION 2.8 + 0.5 cm! Sugimoto, T. J Thorac Cardiovasc Surg 1999;117:463-71

Late TR after Functional MR Surgery Matsunaga, Duran. Circulation 2005. More TR with TV annulus size

FTR: Reality Mod /severe TR - Bad Dilated annulus - Bad

Tricuspid Valve Repair- Does it matter? matter 311 Patients MV Repair Preop TR 0.7 0.9 93 % no/trace/mild 7 % moderate NONE Severe! Dreyfus Annals of Thoracic Surgery 2005

TR Does Not Just Go Away After MVr 311 undergoing MVr, mostly degenerative, all with dilated TV annulus TR Worsening by > 2 Grades 60 50 40 30 20 10 0 48% MVR only P<0.001 2% MVR+TVR Dreyfus. Ann Thorac Surg 2005;79:127.

Undersized TV repair for FTR Actually Re-NORMAL size!

Undersized TV repair for FTR Preoperative None Mild Moderate Mod-to- Severe Severe Predischarge TR Grade None Mild Moderate Mod-to- Severe Severe Follow-up (mean = 1 yr) None Mild Moderate Mod-to- Severe Severe

Far less TR, better RV NO mortality or PPM

Outcomes of Guideline directed repair of FTR performed during MV surgery Ward, Romano, Bolling : JTCVS 2018 262 pts TVr, mod or < mod TR, 26/28/30 ring No mortality, No TS, RV improved 1% progression to severe TR, 2.6 % de novo PPM rate

FTR : Reality Mod/severe TR - BAD TR ring - GOOD

Do many patients have TR? STS Database: 58,000 Patients Isolated MR Moderate TR: 12.4 % Severe TR: 7.1 % Moderate or Severe 19.5% Mayo: 115/699 Matsuyama: 46/174 16% Mod/Sev TR 26% Mod + TR Gammie JS Annals of Thoracic Surgery 2009 Yilmaz J Thorac Cardiovasc Surg 2011;142:608 Matsuyama Ann Thorac Surg 2003;75:1826

Annular Dilation / Shape Change of FTR : 40 20 75%- all cases of MR!! 40 20 0-40 -20 0 20 40-20 -40 0-40 -20 0 20 40-20 -40 Normal Tricuspid Annulus Fukuda. Circulation. 2006;114:I-492. Tricuspid Annulus with Functional TR

TR is ignored! STS Database 60,000 MR + TR MR - 4,000,000 TR - 1,600,000 250,000 Annual New MR Annual MR Surgeries Annual TR Surgeries 7,000 TVr

Why Not Fix TR at Surgery? I HATE PACEMAKERS! 136 pts, mostly TV repair 8 yr follow up, PPM in 21%,

Tricuspid Repair Rate when fixing MR Based on Preop TR Grade 100 Percent of Patients Having Tricuspid Repair 80 60 40 39 79 20 0 1 3.9 None Mild Moderate Severe Preoperative TR Grade Source: STS Database, N = 46500 V 2.73 2011-2013

FTR: Reality Mod/severe TR - Bad TR ring - Good TVR - Sad

Percutaneous Implications for TR

FTR: Percutaneous Not Rings

Tricuspid Regurgitation 4-TECH

Tricuspid Regurgitation Mitralign Trialign

FTR: Perc McKay? FAILED

2 Pair 4 pledgets 2 Locks Target: Full Posterior Annulus 29

Pre Procedure Post 1 st Pair Post 2 nd Pair Perc DeVega?

12/14 patients received one pair of implants Average annular reduction 35% Average EROA reduction 58% Adverse event 1 access complication Annular Area cm2 EROA cm2 25 5 4.5 20 10 cm2! 4 1.5 cm2! 3.5 15 3 2.5 2 10 1.5 5 1 0.5 0 0 Pre Procedure Post Procedure Pre Procedure Post Procedure 31

Tricuspid Percutaneous - Myth TR goal is different.. TR grades 1-4 and 5+ massive 6+ torrential

FTR: Percutaneous other things Remain calm! Carry on!

FTR Surgery : Percutaneous Implications TV Perc Rings!

Tricuspid Regurgitation Cardioband

Pre-op Echo : 4+ MR, 3-4+ TR Millipede 36

Post MVR / TVR Millipede FLUORO 37

24 month Post MVR / TVR Millipede TTE 38

24 month Post MVR / TVR Millipede TTE 39

Tricuspid Regurgitation - Reality TR is BAD The biology of TR will not change with the method of therapy A new grading method will not fool nature

TR severity - reality Sustained, meaningful reduction of TR

TR Percutaneous : Myth and reality Less impact Earlier intervention Best TR is zero Good enough? 1-2+TR Reality : Huge market - $$ Patients want it it will happen